Matritech gets grant for cancer tests:
This article was originally published in Clinica
Executive Summary
Matritech has been awarded a Small Business Innovation Research Grant from the National Cancer Institute for the further development of Nuclear Matrix Protein (NMP) tests for the detection and management of bladder and colon cancer. Matritech is working on tests based on Nuclear Mitotic Apparatus which are believed to improve the clinical accuracy of blood and urine-based tests. The US company has developed two tests: NMP22 for bladder cancer which received US marketing approval in 1996; and the NuMA for colon cancer which was submitted to the FDA in October last year.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.